Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogene-modified Antigen-specific T (IgT) Cells for the Treatment of Glioblastoma Multiforme

NCT03170141 is registered in ClinicalTrials.gov with Shenzhen Geno-Immune Medical Institute as lead sponsor.

NCT NCT03170141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03170141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogene-modified Antigen-specific T (IgT) Cells for the Treatment of Glioblastoma Multiforme
Lead sponsor
Shenzhen Geno-Immune Medical Institute
Phase
Phase 1
Overall status
Terminated
Start date
May 31, 2017
Completion date
July 31, 2026
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain cancer, glioblastoma multiforme of brain